Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05747053
Status:
TERMINATED
Last Update Posted:
2024-02-26
First Post:
2023-01-27
Brief Title:
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Sponsor:
George Washington University
Organization:
George Washington University
Study Overview
Official Title:
Surveillance Testing Utilizing AlloSure to Assess Rejection Following Transplantation and Personalization of Immunosuppressive Therapy
Status:
TERMINATED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
will NOT resume
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STAART
Brief Summary:
Long-term graft failure rates continue to be unacceptably high despite the development of immunosuppressive drugs underscoring the unmet need for robust prognostic biomarkers of allograft injury and failure While rates of acute rejection AR continue to decrease it remains the strongest predictor of long-term allograft survival and so having a better understanding of factors predicting AR may contribute to more individualized patient care Selecting optimum immunosuppressive dosage is another factor in personalizing kidney care This project will study two areas of individualized kidney care 1 assessing rejection by surveillance testing utilizing AlloSure 2 developing an algorithm to select optimum immunosuppressive medication dosage
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None